Drug Profile
Interferon alpha-2b - Beijing Kawin Technology
Alternative Names: Interferon alpha-2b vaginal effervescent tablet - Beijing Kawin technology; Recombinant human interferon alpha-2b injection - Beijing Kawin technologyLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Basal cell cancer; Chronic myeloid leukaemia; Condylomata acuminata; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Herpes zoster; Kaposi's sarcoma; Lymphoma; Malignant melanoma; Multiple myeloma; Ovarian cancer; Renal cancer; Uterine diseases
Most Recent Events
- 27 Aug 2015 Launched for Basal cell cancer in China (Intratumoural) before August 2015
- 27 Aug 2015 Launched for Chronic myeloid leukaemia in China (IM) before August 2015
- 27 Aug 2015 Launched for Condylomata acuminata in China (IM) before August 2015